MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter

MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click:

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, March 5, 2016

MS SMART -Multiple Sclerosis - Secondary Progressive Multi-Arm Randomisation Trial

Update 1st April 2015 MS-SMART has started and recruitment into the trial will continue through 2015. Two centres are currently open and all centres taking part will be open soon.
Multiple sclerosis (MS) is a disabling and progressive neurological disease that affects approximately 100,000 people in the UK. The secondary progressive (SPMS) stage of disease results not in individual attacks but slow, cumulative and irreversible disability affecting walking, balance, vision, cognition, pain control and bladder and bowel function. Critically, and unlike early disease, there is no proven treatment for the late stage of MS. This is therefore an urgent and major unmet health need.

MS-SMART will test 3 drugs (riluzole, amiloride and fluoxetine) in 440 people with SPMS. The drugs were selected from a group of medicines that are used to treat other conditions and show promising signs in the treatment of MS (in particular SPMS). Amiloride is used to treat heart disease, fluoxetine (depression) and riluzole (motor neurone disease).
It will take approximately one year to screen and recruit people into the trial. Participants will take one of the drugs OR a placebo pill (a dummy pill) for two years. No one will know which treatment they are taking while the trial in on-going. ‘Blinding’ as this is known is widely used in clinical trials and ensures the results of the trial are not subject to bias. During the trial participants will have a number of clinic assessments and Magnetic Resonance Imaging (MRI) scans.

Listed below is the MAIN criteria for taking part in the MS-SMART trial. A detailed screening process is required to make sure the trial is suitable and safe for someone to take part in.
ü Secondary Progressive MS
ü Not on DMT (Disease Modifying Treatment)
ü Not taking a SSRI (Selective Serotonin Re-uptake Inhibitor), a type of anti-depressant
ü Still able to walk at least 20 metres (with the support of 2 crutches) or up to 500 metres without help
ü Aged 25-65 (inclusive)

Please note that MS-SMART is an academically led trial. It is not an international trial and recruitment can only take place in the UK.

How is MS-SMART funded?The MS-SMART trial is independent research awarded by the Efficacy and Mechanism Evaluation Programme (EME), a partnership between the Medical Research Council (MRC) and the National Institute for Health Research (NIHR), along with the Multiple Sclerosis Society (MS Society) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. MS-SMART is an investigator led project sponsored by University College London (UCL). Additional support comes from the University of Edinburgh and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Sanofi is supporting the study by donating the supply of riluzole for the trial.

If you're interested in finding out about the trial, and whether it might be suitable for you, why not let us know?

Clinical staff will be in contact with you to discuss the trial in more detail as soon as they can. It will take several months to contact everyone interested in the trial because there has been huge interest in the trial. We are extremely grateful to everyone who has contacted us already.
Progress about the trial will be updated on this website.

MS Views and News 


No comments: